Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer – A retrospective cohort study
Open Access
- 1 October 2021
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 59, 67-75
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Research Institute
This publication has 44 references indexed in Scilit:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Trastuzumab containing regimens for early breast cancerCochrane Database of Systematic Reviews, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Treatment of HER2-positive breast cancer: current status and future perspectivesNature Reviews Clinical Oncology, 2011
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI: Journal of the National Cancer Institute, 2011
- Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancerLaboratory Investigation, 2010
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2007
- Preoperative chemotherapy for women with operable breast cancerCochrane Database of Systematic Reviews, 2007
- Breast carcinoma malignancy grading by Bloom–Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation indexLaboratory Investigation, 2005
- Treatment Resistance of Solid TumorsMedical Oncology, 2001